Publications

PUBLICATIONS

Publications

About DAV132

ArticlesPosters
Chilton CH, Crowther GS, Miossec C, de Gunzburg J, Andremont A, Wilcox MH (2020), Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated Clostridioides (Clostridium) difficile infection (CDI) in an in vitro human gut model. J Antimicrob Chemother
Link
Guk J, Guedj J, Burdet C, Andremont A, de Gunzburg J, Ducher A, Mentré F, Modelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers. PAGE 2019, poster IV-38.
Link
Burdet C, Nguyen TT, Duval X, Ferreira S, Andremont A, Guedj J, Mentré F (2019), Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity. Antimicrob Agents Chemother.
Link
Ducher A, Mentré F, Donazzolo Y, Latreille M, Burdet C, Nguyen TT, Varastet M, Sablier F, Augustin V, Hugon P, Ferreira S, Andremont A, de Gunzburg J, Dose-effect and safety of DAV132, an activated charcoal based product, when given with oral moxifloxacin on free moxifloxacin fecal concentrations and intestinal microbiota diversity: a randomized controlled trial in 144 healthy volunteers. ECCMID 2018, poster 0758.
Link
Saint-Lu N, Burdet C, Sablier-Gallis F, Corbel T, Nevière A, Sayah-Jeanne S, Pulse M, Weiss W, Ferreira S, Andremont A, Mentré F, de Gunzburg J (2019) , DAV131A protects hamsters from lethal Clostridioides difficile infection induced by fluoroquinolones. Antimicrob Agents Chemother.
Link
Burdet C, Nguyen TT, Saint-Lu N, Sayah-Jeanne S, Hugon P, Sablier-Gallis F, Ferreira S, Andremont A, Mentré F, de Gunzburg J, Change in bacterial diversity of fecal microbiota drives mortality in a hamster model of antibiotic-induced Clostridium difficile colitis. IDWEEK 2017, poster 1251.
Link
Burdet C, Sayah-Jeanne S, Nguyen TT, Hugon H, Sablier-Gallis F, Saint-Lu N, Corbel T, Ferreira S, Pulse M, Weiss WJ, Andremont A, Mentré F, de Gunzburg J (2018), Antibiotic-induced dysbiosis predicts mortality in an animal model of Clostridium difficile infection. Antimicrob Agents Chemother.
Link
Saint-Lu N, Sayah-Jeanne S, Sablier-Gallis F, Pulse M, Burdet C, Nguyen TT, Mentré F, Chachaty E, Andremont A, de Gunzburg J, Extended protection by DAV131A against antibiotic-induced Clostridium difficile infection in hamsters. ASM Microbes 2016.
Link
de Gunzburg et al. (2018), Protection of the Human Gut Microbiome From Antibiotics. The Journal of Infectious Diseases, Volume 217, Issue 4, Pages 628–636.
Link
de Gunzburg et al., DAV132, an Adsorbent-Based Product, Protects the Gut Microbiome and Prevents Clostridium difficile Infections during Moxifloxacin Treatments. IDWEEK 2015, poster 129_760.
Link
Burdet C, Sayah-Jeanne S, Nguyen TT, Miossec C, Saint-Lu N, Pulse M, Weiss W, Andremont A, Mentré F, De Gunzburg J (2017), Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis. Antimicrob Agents Chemother.
Link
Miossec C, Sayah-Jeanne S, Augustin V, Chachaty E, Weiss W, Murphy T, Pulse M, Andremont A, de Gunzburg J, DAV131, an oral adsorbent-based product, exerts a dose-dependent protection of hamsters against moxifloxacin-induced Clostridium difficile lethal infection. ECCMID 2014, poster P0804.
Link
De Gunzburg, Ducher, Modess, Wegner, Oswald, Dressman, Augustin, Feger, Andremont, Weitschies and Siegmund (2014), Targeted adsorption of molecules in the colon with the novel adsorbent-based Medicinal Product, DAV132: A proof of concept study in healthy subjects. The Journal of Clinical Pharmacology.
Link
Ducher A, Modess C, Weitschies W, Siegmund W, Dressman J, Augustin V, Feger C, Andremont A, de Gunzburg J, DAV132, developed to prevent side effects of antibiotics in the gut flora: Results of a pilot cross-over study in healthy volunteers. ECCMID 2014, poster P0248.
Link
Grall N, Massias L, Nguyen TT, Sayah-Jeanne S, Ducrot N, Chachaty E, de Gunzburg J, Andremont A (2013), Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice. Antimicrob Agents Chemother.
Link
Miossec C, Sayah-Jeanne S, Augustin V, Chachaty E, Weiss W, Pulse M, Murphy T, Andremont A, de Gunzburg J, DAV131, an Oral Adsorbent-based Product Fully Protects Hasmters Against Moxifloxacin induced Clostridium difficile Lethal Infection. ICAAC 2013, poster F-631a.
Link
Grall N, Chachaty E, Sayah-Jeanne S, de Gunzburg J, Andremont A, Can DAV132, a Medical Device Releasing an Adsorbent into the Late Ileum, Decrease Significantly the Impact of Antibiotics on the Fecal Microbiota?. ICPIC 2013, Geneva.
Link
Sayah-Jeanne S, Chachaty E, Nguyen T, Augustin V, de Gunzburg J, Mentré F, Andremont A. Decrease of Levofloxacin Fecal Concentrations in Experimental Dogs Using DAV132, an Oral Adsorbent Delivered to the Ileum/Colon.ICAAC 2012.
Link

About C. difficile infection

ArticlesPosters
Lurienne L, Bandinelli PA, Galvain T, Coursel CA, Oneto C, Feuerstadt P (2020), Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. Journal of Patient-Reported Outcomes.
Link
Lurienne L, Bandinelli PA, Galvain T, Coursel CA, Boutier P, Oneto C, Feuerstadt P. Perception of Quality of Life Among People Experiencing or Having Experienced a Clostridium difficile Infection in the United States: Qualitative Review of Respondents Verbatim. ACG 2018, poster P1877.
Link
Duhalde L, Lurienne L, Wingen-Heimann SM, Guillou L, Buffet R, Bandinelli PA (2019), Excess burden associated with Clostridioides difficile infection in haematological patients occurring during hospitalization with induction chemotherapy in the United States. Journal of Hospital Infection.
Link
Leblanc S, Blein C, Andremont A, Galvain T, Bandinelli PA. Burden of Clostridium difficile Infection in French Hospital in 2014 From the National Health Insurance Perspective. RICAI 2016.
Link
Mollard S, Lurienne L, Heimann SM, Bandinelli PA (2019), Burden of Clostridium (Clostridioides) difficile infection during inpatient stays in the USA between 2012 and 2016. Journal of Hospital Infection.
Link
Leblanc S, Blein C, Andremont A, Bandinelli PA, Galvain T (2017), Burden of Clostridium difficile Infection in French Hospital in 2014 From the National Health Insurance Perspective. Infection Control & Hospital Epidemiology, Volume 38 Issue 8.
Link

About Resistance to Antibiotics

ArticlesPosters
Dupouy VM, Abdelli M, Moyano G, Arpaillange N, Bibbal D, Cadiergues MC, Lopez-Polin D, Sayah-Jeanne S, de Gunzburg J, Saint-Lu N, Gonzalez-Zorn B, Andremont A, Bousquet-Mélou A (2019), Prevalence of beta-lactam and quinolone/fluoroquinolone resistance in Enterobacteriaceae from dogs in France and Spain - Characterization of ESBL/pAmpC isolates, genes and conjugative plasmids. Front. Vet. Sci.
Link
Nguyen TT, Chachaty E, Huy C, Cambier C, Mentre F, de Gunzburg J, Andremont A (2011), Correlation between Fecal Concentrations of Ciprofloxacin and Fecal Counts of Resistant Enterobacteriaceae in Piglets Treated with Ciprofloxacin: toward New Means To Control the Spread of Resistance?. Antimicrob Agents Chemother.
Link

About Immuno-Oncology

ArticlesPosters
Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, Buffet R, Bandinelli PA (2020), Non-small-cell lung cancer immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis.
J Thorac Oncol
Link